Sanofi SA (NASDAQ:SNY) on Wednesday decided not to renew the Director mandate of Paul Hudson.

As a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his tenure of six years with the company.

Succession Plan And Governance Actions

The Board of Directors appointed Belén Garijo as Chief Executive Officer. She will take up her duties at the end of the Group’s Annual General Meeting on April 29, 2026. The Board will also propose to the shareholder vote the candidacy of Belén Garijo as a director of the Group.

Olivier Charmeil, Executive Vice President, General Medicines, will assume the role of Interim Chief Executive Officer during this transition.

Belén Garijo will bring an increased rigor to the implementation of Sanofi’s strategy and accelerate the preparation of the Group’s future. Her priority will be to strengthen the productivity, governance, and innovation capacity of Research & Development.

Belén Garijo joined Merck KGaA